Save Money While Seeking the Sun: Cost Effective Winter Stays in Egypt
25.1.2023 11:00:00 EET | Business Wire | Press release
Spending the winter season in a warm place has always been popular, whether you’re a digital nomad or a pensioner. But, the rising cost of living over the past year could cause many to reconsider whether, or how, they travel.
While Egypt has long been on travelers’ radar, thanks to its low-cost of living, it has now become a popular long-stay winter destination. In fact, a one month stay in a luxurious three or four-star-hotel can cost less than living in the Western European countries for the same amount of time.
Research collated by the Egyptian Government from a variety of tour operators shows a four-week winter sun stay costs, on average, €1 218 per couple. This includes 160€ per person for a return flight, 25€ per couple for a double room in a four-star hotel and 8€ per person for a three-course dinner at a local restaurant.
In comparison, the average monthly cost of a two-person household for gas, energy, food and beverages is 1 396€ in Italy, 1 509€ in France and 1 601€ in Germany during the winter.
The Egyptian Government is currently promoting and facilitating month long stays at a wide variety of hotels.
Amr El-Kady, CEO of Egyptian Tourism Authority, said: “Egypt is always happy to welcome travelers from Europe. We are doing our best to make the stay as effortless and affordable as possible. This winter season, we invite you to spend the cold months under the kind Egyptian sun, saving the budget and filling life with fantastic new experiences”.
What does Egypt have to offer? Plenty.
From Cairo to Luxor, from the beguiling desert to the lush delta of the Nile, Egypt is a traveler's dream. Whether diving into the rich underwater world of the Red Sea, sailing on the Nile towards the sunset or tracing the secrets of the ancient Egyptians in stunning temple complexes, the land of the pharaohs has something to offer to every visitor.
Among the most famous destinations is the capital Cairo, where you can immerse yourself in all eras of Egyptian history in the Egyptian Museum, and visit the famous Pyramids of Giza with the impressive Sphinx. Another highlight is the city of Luxor, which offers some spectacular wonders, that include the Valley of the Kings, the Temple of Karnak and the legendary Luxor Temple, which is one of the absolute must-sees on any trip and continues to enchant with ancient stories.
If you prefer active and adventurous activities, you don't have to look far. Egypt is not only a diver's paradise, but also offers desert excursions, Nile cruises and breathtaking landscapes such as the Colored Canyon National Park on the Sinai Peninsula. While ecotourism is becoming increasingly popular in the country and even spiritual tours are offered, Egypt is also known for particularly high-quality spa treatments.
A variety of flight connections ensure a pleasant way to get there. There are direct flights to resorts of Egypt from almost every major European city.
Find out what else Egypt has to offer on Egypt travel - Home (experienceegypt.eg)
- ENDS –
Destination images can be downloaded here
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005579/en/
Contact information
External Press office
Philipp Koneev, Senior Account Manager, MC Group
p.koneev@mcgroup.com
+49 30 65000‑540
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
